Amicus Therapeutics (FOLD) Reports Q2 Loss of $0.34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
August 7, 2017 7:00 AM EDTÂ Â Â Â Â Â Â 179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 On Target to Reach 300 Patients by Year-End 2017
Migalastat NDA Submission Targeted for 4Q17
Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17
CRANBURY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced financial results for the second quarter ended June 30, 2017. The Company also provided... More
